Immune Pharmaceuticals (NASDAQ:IMNP) Upgraded by ValuEngine to “Sell”

Immune Pharmaceuticals (NASDAQ:IMNP) was upgraded by investment analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued on Friday, February 2nd.

Separately, Maxim Group began coverage on Immune Pharmaceuticals in a report on Friday, January 5th. They set a “buy” rating and a $3.00 price objective on the stock.

Immune Pharmaceuticals (NASDAQ IMNP) opened at $0.49 on Friday. Immune Pharmaceuticals has a 1-year low of $0.40 and a 1-year high of $5.02. The company has a current ratio of 0.03, a quick ratio of 0.03 and a debt-to-equity ratio of 3.04. The firm has a market capitalization of $8.76, a PE ratio of -0.16 and a beta of 2.16.

An institutional investor recently raised its position in Immune Pharmaceuticals stock. Susquehanna International Group LLP increased its holdings in shares of Immune Pharmaceuticals Inc (NASDAQ:IMNP) by 41.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 69,805 shares of the biopharmaceutical company’s stock after purchasing an additional 20,488 shares during the period. Susquehanna International Group LLP owned approximately 0.69% of Immune Pharmaceuticals worth $215,000 at the end of the most recent quarter. Institutional investors and hedge funds own 1.60% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://stocknewstimes.com/2018/02/19/immune-pharmaceuticals-imnp-rating-increased-to-sell-at-valuengine.html.

Immune Pharmaceuticals Company Profile

Immune Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company’s segment is acquiring, developing and commercializing prescription drug products.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Immune Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply